Media Articles Related to Istodax (Romidepsin)
Romidepsin can reverse HIV latency in patients on long-term ART without compromising T-cell function
Source: HIV / AIDS News From Medical News Today [2015.09.18]
A cure for HIV requires the eradication of latent (i.e., dormant and therefore hidden) virus from reservoirs in immune cells throughout the body.
Social deprivation and gender affects incidence of Hodgkin lymphoma in children and young adults
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.09.28]
Living in overcrowded conditions appears to protect children and young adults against developing a particular type of Hodgkin lymphoma (HL), a cancer that originates from the lymphocytes (white...
Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.09.22]
A study, published online in Blood, the Journal of the American Society of Hematology (ASH), reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin...
CAR T-cell therapy trial yields early promise for lymphoma andleukemia patients
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.09.17]
In a phase I/IIa trial, third-generation CD19 CAR T-cell therapy combined withchemotherapy pretreatment resulted in complete response in some lymphoma and leukemiapatients, according to data...
Source: MedicineNet Biological Therapy Specialty [2015.04.01]
Title: Non-Hodgkin's Lymphoma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/1/2015 12:00:00 AM
Published Studies Related to Istodax (Romidepsin)
Romidepsin for peripheral T-cell lymphoma. 
Peripheral T-cell lymphoma (PTCL) is comprised of a rare heterogeneous group of
diseases with diverse clinical presentations; however outcomes associated with
conventional chemotherapy are generally poor in the majority of patients. Newer
approaches, which include dose-intensification and agents with novel mechanisms
of action, are needed to improve outcomes in this group of patients...
Romidepsin: a novel histone deacetylase inhibitor for cancer. [2011.08]
Introduction: Romidepsin is a novel histone deacetylase (HDAC) inhibitor, with a recent approval for treatment of cutaneous T-cell lymphoma (CTCL).Future directions include expanded indications in T-cell lymphomas as well as novel combinations with other HDAC inhibitors and other therapeutic agents.
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. [2011.08]
Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration. This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample...
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. [2011.06.02]
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and peripheral (PTCL) T-cell lymphoma... The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL.
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. [2011.05]
Romidepsin, a potent histone deacetylase inhibitor, has shown activity in preclinical glioma models. The primary objectives of this trial were to determine the pharmacokinetics of romidepsin in patients with recurrent glioma on enzyme-inducing antiepileptic drugs (EIAEDs) and to evaluate the antitumor efficacy of romidepsin in patients with recurrent glioblastoma who were not receiving EIAEDs...
Clinical Trials Related to Istodax (Romidepsin)
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation [Not yet recruiting]
The goal of this clinical research study is to learn if giving romidepsin before and after a
stem cell transplant in combination with fludarabine and busulfan can help to control
leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of
romidepsin that can be given with this combination.
The safety of this combination and the safety of giving romidepsin after a stem cell
transplant will also be studied.
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma [Recruiting]
The goal of this clinical research study is find the highest tolerable dose of romidepsin
that can be given in combination with ifosfamide, carboplatin, etoposide (ICE) to patients
with PTCL. The safety of this drug combination will also be studied.
Romidepsin is designed to stop the growth of cancer cells and block new blood vessels from
forming around the cancer cells. This may cause the cancer cells to die.
Ifosfamide and etoposide are designed to slow or stop the growth of cancer cells.
Carboplatin is designed to interfere with the growth of cancer cells by stopping cell
division, which may cause the cells to die.
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer [Completed]
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer [Completed]
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma [Recruiting]
This a multi-center, single arm, open-label, Phase I dose-finding and preliminary efficacy
study of the combination of the histone deacetylase inhibitor romidepsin (Istodax®) in
combination with doxorubicin HCl liposomal (Doxil®) for adult patients with relapsed or
refractory cutaneous T-cell lymphoma after at least 2 lines of skin-directed therapy or one
prior line of systemic therapy. Patients will be treated with Doxil 20mg/m2 on day 1 and
romidepsin 8-14mg/m2 on days 1, 8 and 15, every 28 days, until 2 cycles beyond the best
response, 8 cycles, disease progression or intolerability whichever comes first.
Importanly, doxil is administered prior to romidepsin on day1 of each cycle. Patients will
be followed until disease progression or death whichever comes first.
Reports of Suspected Istodax (Romidepsin) Side Effects
Decreased Appetite (6),
Pulmonary Oedema (5),
Infusion Site Extravasation (4),
Peripheral Sensory Neuropathy (4),
General Physical Health Deterioration (4),
Febrile Neutropenia (4), more >>